Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD (GeneQuest)

Regional University Hospital Center (CHRU)

Status: Completed

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Treatments: Other: Blood Collection

Study type: Interventional

Funder types: Other

Identifiers

NCT02112136

RB14.017 GeneQuest

Details and patient eligibility

About

The aim of this study is to identify families with ADPKD , characterize the phenotype and screen for mutations in known genes (PKD1 and PKD2, and then HNF1b and UMOD in PKD1 PKD2 negative carriers).

Genome wide analysis will be performed in families without mutations identified.

Full description

• Inclusion of ADPKD patients in 20 different centers of Nephrology in the Western part of France
• Characterization of the Phenotype
• Collect DNA sample
• Analysis of PKD1 and PKD2 genes first
• Analysis of HNFIb and UMOD for PKD1 and PKD2 negative patients
• Recruitment of affected and non-affected relatives of PKD1 and PKD2 negative ADPKD patients
• Identify new genes involved in ADPKD using exome sequencing in PKD1 and PKD2 negative pedigrees

Enrollment: 1,450 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for the proband :

• Patients with a diagnosis of ADPKD
• Written Informed Consent
• Affiliated or benefiting from a national insurance

Inclusion Criteria of the relatives (affected or non affected) :

• Relatives with a diagnosis of ADPKD (ADPKD relatives)
• And Relatives over age 30 for whom the diagnosis of ADPKD has been discarded (non ADPKD relatives) with renal ultrasonography performed after age 30.
• Written Informed consent
• Affiliated or benefiting from a national insurance

Exclusion Criteria for the Probands:

• Subjects unable to provide written informed consent
• Previous Molecular analysis of PKD1 and PKD2 genes with identification of the pathogenic mutation

Exclusion criteria for the Relatives:

• Subjects unable to provide written informed consent
• Age under 30 for the "non-affected" relatives

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1,450 participants in 1 patient group

GeneQuest

Other group

Description:

* No drug will be administrated in this study * Blood collection

Treatment:

Other: Blood Collection